Summary

Pulmonary embolism (PE) is one of the most common preventable causes of death (responsible for >100,000 deaths annually) and the third leading cause of cardiovascular mortality. New data from the Moderate Pulmonary Embolism Treated with Thrombolysis [MOPETT] study suggest that moderate PE patients may be managed with reduced-dose issue plasminogen activator and modified anticoagulation.